Recommended Label Includes New Indication Based on the Repatha Cardiovascular Outcomes Study (FOURIER)
Amgen Continues to Work Closely With Payers on a Country-by-Country Basis to Ensure Access to Repatha for High-Risk Cardiovascular Patients
PR Newswire
THOUSAND OAKS, Calif., March 23, 2018